Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer

NCT05472467 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: Camrelizumab
RADIATION: stereotactic body radiation therapy
DRUG: Chemotherapy

Sponsor

Sichuan Cancer Hospital and Research Institute